标题 |
A phase 4 clinical study to compare the safety and efficacy of LONQUEX® with NEULASTA® and Placebo in patients with Non-Small-Cell Lung Cancer treated with first-line chemotherapy
LONQUEX®与NEULASTA®和安慰剂在接受一线化疗的非小细胞肺癌患者中的安全性和有效性比较的4期临床研究
|
网址 | |
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
其它 | 年份2015,作者"EUCTR SK",部分摘要:INTERVENTION: Trade Name: LONQUEX Pharmaceutical Form: Solution for injection INN or Proposed INN: LIPEGFILGRASTIM CAS Number: 1117844‐87‐7 Current Sponsor code: XM22 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: NEULASTA Pharmaceutical Form: Solution for injection INN or Proposed INN: PEGFILGRASTIM CAS Number: 208265‐92‐3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ CONDITION: Advanced squamous or non‐squamous non‐small‐cell lung cancer (NSCLC) Stage IIIB/IV ; MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non‐small cell lung cancer stage IV System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
求助人 | |
下载 |